LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Jennifer A. Chan, Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos, Bhavana Konda, N. Vijayvergia, N.A. Dasari, J. Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt